clinical trial · NCT05180708
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Pachyonychia CongenitaQTORIN 3.9% rapamycin anhydrous gelVehicle
brief summary
This study evaluates the safety and efficacy of QTORIN 3.9% rapamycin anhydrous gel in the treatment of adults with Pachyonychia Congenita. This study includes a screening period, baseline period and 6-month treatment period.
started
Nov 29, 2021
primary completion
Jun 30, 2023
completion
Jun 30, 2023
last updated
Aug 29, 2024
official title
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol